Display options
Cite
Catalá-López F, García-Altés A, Alvarez-Martín E, et al. Does the development of new medicinal products in the European Union address global and regional health concerns?. Popul Health Metr. 2010;8:34doi: 10.1186/1478-7954-8-34.
Catalá-López, F., García-Altés, A., Alvarez-Martín, E., Gènova-Maleras, R., & Morant-Ginestar, C. (2010). Does the development of new medicinal products in the European Union address global and regional health concerns?. Population health metrics, 834. https://doi.org/10.1186/1478-7954-8-34
Catalá-López, Ferrán, et al. "Does the development of new medicinal products in the European Union address global and regional health concerns?." Population health metrics vol. 8 (2010): 34. doi: https://doi.org/10.1186/1478-7954-8-34
Catalá-López F, García-Altés A, Alvarez-Martín E, Gènova-Maleras R, Morant-Ginestar C. Does the development of new medicinal products in the European Union address global and regional health concerns?. Popul Health Metr. 2010 Dec 20;8:34. doi: 10.1186/1478-7954-8-34. PMID: 21172012; PMCID: PMC3017015.
Copy Download .nbib Format: NLM
Share it on

Popul Health Metr. 2010 Dec 20;8:34. doi: 10.1186/1478-7954-8-34.

Does the development of new medicinal products in the European Union address global and regional health concerns?.

Population health metrics

Ferrán Catalá-López, Anna García-Altés, Elena Alvarez-Martín, Ricard Gènova-Maleras, Consuelo Morant-Ginestar

Affiliations

  1. Fundación Instituto de Investigación en Servicios de Salud, Valencia, Spain. [email protected].

PMID: 21172012 PMCID: PMC3017015 DOI: 10.1186/1478-7954-8-34

Abstract

BACKGROUND: Since 1995, approval for many new medicinal products has been obtained through a centralized procedure in the European Union. In recent years, the use of summary measures of population health has become widespread. We investigated whether efforts to develop innovative medicines are focusing on the most relevant conditions from a global public health perspective.

METHODS: We reviewed the information on new medicinal products approved by centralized procedure from 1995 to 2009, information that is available to the public in the European Commission Register of medicinal products and the European Public Assessment Reports from the European Medicines Agency. Morbidity and mortality data were included for each disease group, according to the Global Burden of Disease project. We evaluated the association between authorized medicinal products and burden of disease measures based on disability-adjusted life years (DALYs) in the European Union and worldwide.

RESULTS: We considered 520 marketing authorizations for medicinal products and 338 active ingredients. New authorizations were seen to increase over the period analyzed. There was a positive, high correlation between DALYs and new medicinal product development (ρ = 0.619, p = 0.005) in the European Union, and a moderate correlation for middle-low-income countries (ρ = 0.497, p = 0.030) and worldwide (ρ = 0.490, p = 0.033). The most neglected conditions at the European level (based on their attributable health losses) were neuropsychiatric diseases, cardiovascular diseases, respiratory diseases, sense organ conditions, and digestive diseases, while globally, they were perinatal conditions, respiratory infections, sense organ conditions, respiratory diseases, and digestive diseases.

CONCLUSIONS: We find that the development of new medicinal products is higher for some diseases than others. Pharmaceutical industry leaders and policymakers are invited to consider the implications of this imbalance by establishing work plans that allow for the setting of future priorities from a public health perspective.

References

  1. Am J Prev Med. 2006 Mar;30(3):269-76 - PubMed
  2. JAMA. 2004 Jun 2;291(21):2616-22 - PubMed
  3. BMJ. 2002 Mar 23;324(7339):702 - PubMed
  4. BMJ. 2002 Aug 3;325(7358):269-71 - PubMed
  5. Eur J Public Health. 2003 Sep;13(3):246-51 - PubMed
  6. JAMA. 2010 Jan 13;303(2):137-43 - PubMed
  7. Rev Esp Salud Publica. 2009 Jan-Feb;83(1):137-51 - PubMed
  8. Eur J Clin Pharmacol. 2007 Sep;63(9):879-89 - PubMed
  9. Eur J Clin Pharmacol. 2003 Nov;59(8-9):701-6 - PubMed
  10. Lancet. 2001 Jul 7;358(9275):64-7 - PubMed
  11. Br J Psychiatry. 2007 Feb;190:91-3 - PubMed
  12. N Engl J Med. 1999 Jun 17;340(24):1881-7 - PubMed
  13. Br J Cancer. 2005 Sep 5;93(5):504-9 - PubMed
  14. BMJ. 2007 Oct 20;335(7624):803-5 - PubMed
  15. Rev Esp Salud Publica. 2001 Jul-Aug;75(4):281-3 - PubMed
  16. Bull World Health Organ. 2001;79(11):1076-84 - PubMed
  17. Eur J Clin Pharmacol. 2003 May;59(1):79-84 - PubMed

Publication Types